Drug Information

Drug General Information
Drug ID
D0S0WN
Former ID
DCL000070
Drug Name
Biomed 101
Drug Type
Small molecular drug
Indication Renal cancer [ICD9: 140-229, 189; ICD10:C64] Discontinued in Phase 1 [521466]
Therapeutic Class
Anticancer Agents
Company
Intarcia Therape.
Structure
Download
2D MOL

3D MOL
Formula
C28H36O7
Canonical SMILES
CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)<br />C)OC)CCC
InChI
1S/C28H36O7/c1-5-8-21-23(13-10-19-11-14-25(28(30)31)35-26(19)21)33-16-7-17-34-24-15-12-20(18(3)29)27(32-4)22(24)9-6-2/h10,12-13,15,25H,5-9,11,14,16-17H2,1-4H3,(H,30,31)
InChIKey
ZVVCSBSDFGYRCB-UHFFFAOYSA-N
PubChem Compound ID
114999
PubChem Substance ID
10236589, 12014315, 14932652, 29296580, 50070437, 50071080, 53407382, 57338938, 85210640, 99222704, 103177985, 103916040, 104397364, 129962393, 134338773, 134341624, 135073323, 137174699, 142400984, 162379975, 162474333, 178102777, 228057561, 249792663
Target and Pathway
Target(s) Leukotriene B4 receptor 1 Target Info Binder [550277]
KEGG Pathway Neuroactive ligand-receptor interaction
NetPath Pathway IL4 Signaling Pathway
Reactome Leukotriene receptors
G alpha (q) signalling events
WikiPathways Nucleotide GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signaling
References
Ref 521466ClinicalTrials.gov (NCT00004890) Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer. U.S. National Institutes of Health.
Ref 550277Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.